PMID- 30687097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and 
      Anti-inflammatory Drugs in Pre-clinical and Clinical Stages.
PG  - 1536
LID - 10.3389/fphar.2018.01536 [doi]
LID - 1536
AB  - Despite the progress that has occurred in recent years in the development of 
      therapies to treat painful and inflammatory diseases, there is still a need for 
      effective and potent analgesics and anti-inflammatory drugs. It has long been 
      known that several types of antioxidants also possess analgesic and 
      anti-inflammatory properties, indicating a strong relationship between 
      inflammation and oxidative stress. Understanding the underlying mechanisms of 
      action of anti-inflammatory and analgesic drugs, as well as essential targets in 
      disease physiopathology, is essential to the development of novel therapeutic 
      strategies. The Nuclear factor-2 erythroid related factor-2 (Nrf2) is a 
      transcription factor that regulates cellular redox status through endogenous 
      antioxidant systems with simultaneous anti-inflammatory activity. This review 
      summarizes the molecular mechanisms and pharmacological actions screened that 
      link analgesic, anti-inflammatory, natural products, and other therapies to Nrf2 
      as a regulatory system based on emerging evidences from experimental disease 
      models and new clinical trial data.
FAU - Staurengo-Ferrari, Larissa
AU  - Staurengo-Ferrari L
AD  - Departamento de Patologia, Centro de Ciencias Biologicas, Universidade Estadual 
      de Londrina, Londrina, Brazil.
FAU - Badaro-Garcia, Stephanie
AU  - Badaro-Garcia S
AD  - Departamento de Patologia, Centro de Ciencias Biologicas, Universidade Estadual 
      de Londrina, Londrina, Brazil.
FAU - Hohmann, Miriam S N
AU  - Hohmann MSN
AD  - Departamento de Patologia, Centro de Ciencias Biologicas, Universidade Estadual 
      de Londrina, Londrina, Brazil.
FAU - Manchope, Marilia F
AU  - Manchope MF
AD  - Departamento de Patologia, Centro de Ciencias Biologicas, Universidade Estadual 
      de Londrina, Londrina, Brazil.
FAU - Zaninelli, Tiago H
AU  - Zaninelli TH
AD  - Departamento de Patologia, Centro de Ciencias Biologicas, Universidade Estadual 
      de Londrina, Londrina, Brazil.
FAU - Casagrande, Rubia
AU  - Casagrande R
AD  - Departamento de Ciencias Farmaceuticas, Centro de Ciencias da Saude, Universidade 
      Estadual de Londrina, Londrina, Brazil.
FAU - Verri, Waldiceu A Jr
AU  - Verri WA Jr
AD  - Departamento de Patologia, Centro de Ciencias Biologicas, Universidade Estadual 
      de Londrina, Londrina, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190111
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6337248
OTO - NOTNLM
OT  - Keap1
OT  - Nrf2
OT  - analgesic
OT  - anti-inflammatory
OT  - antioxidant
OT  - inflammation
OT  - oxidative stress
OT  - pain
EDAT- 2019/01/29 06:00
MHDA- 2019/01/29 06:01
PMCR- 2019/01/11
CRDT- 2019/01/29 06:00
PHST- 2018/08/24 00:00 [received]
PHST- 2018/12/17 00:00 [accepted]
PHST- 2019/01/29 06:00 [entrez]
PHST- 2019/01/29 06:00 [pubmed]
PHST- 2019/01/29 06:01 [medline]
PHST- 2019/01/11 00:00 [pmc-release]
AID - 10.3389/fphar.2018.01536 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jan 11;9:1536. doi: 10.3389/fphar.2018.01536. eCollection 
      2018.